Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home News Markets

Drugmakers Have Pledged to Invest $350 Billion in U.S. After Tariff Threat

by Team Lumida
September 17, 2025
in Markets
Reading Time: 3 mins read
A A
0
a room filled with lots of shelves filled with boxes and boxes

Photo by Árpád Czapp on Unsplash

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways

Powered by lumidawealth.com

  • Over a dozen drugmakers have pledged more than $350 billion in U.S. investments by 2030, driven partly by Trump administration tariff threats
  • GSK announced $30 billion in U.S. R&D and supply-chain investment over five years, including a $1.2 billion Philadelphia factory
  • Eli Lilly will build a $5 billion Virginia plant for monoclonal antibodies and bioconjugates, hiring 650 workers
  • Major commitments include Johnson & Johnson ($55 billion over four years) and AstraZeneca ($50 billion by 2030)
  • Trump’s investigation could lead to pharmaceutical tariffs up to 250% over 18 months, though medicines historically exempt
  • European drugmakers face higher exposure due to smaller U.S. manufacturing footprints but are announcing large expansions
  • Morningstar estimates large drugmakers would see 4% profit reduction from U.S. relocation versus 7% without reshoring

What Happened?

Pharmaceutical companies are announcing massive U.S. investment commitments as the Trump administration threatens tariffs on imported medicines. GSK and Eli Lilly joined a growing list of drugmakers pledging hundreds of billions in domestic manufacturing, R&D, and infrastructure spending. These moves aim to mitigate potential tariff impacts while strengthening supply chain resilience following pandemic disruptions.

Why It Matters?

The pharmaceutical reshoring wave represents one of the largest industrial policy responses to Trump’s tariff strategy, potentially transforming global drug manufacturing. The investments could strengthen U.S. pharmaceutical independence while creating thousands of high-skilled jobs. However, the scale of required investment and regulatory timelines highlight the complexity of reshoring critical industries, with implications for drug pricing and supply security.

What’s Next?

Monitor the Trump administration’s pharmaceutical tariff investigation and final policy decisions. Watch for additional drugmaker investment announcements and their impact on global supply chains. Investors should assess opportunities in U.S. pharmaceutical manufacturing, construction, and related services while tracking how reshoring affects company margins and competitive positioning in the global market.

Source
Previous Post

Fed Divisions Thrust Powell Into Uncharted Territory

Next Post

NYC Real-Estate Firm Nears Deal to Buy Troubled Office Landlord Paramount

Recommended For You

Dow Falls 760 Points as Chip Stocks Slide Into Nvidia Earnings, With Micron Down 6% and Nvidia on Pace for Its Worst Month Since April 2022

by Team Lumida
1 hour ago
BlackRock’s Larry Fink on Economic Growth and Market Misconceptions

The Dow fell 760 points as chipmakers slid ahead of Nvidia earnings, with Micron down about 6% and Nvidia off 26% this month.

Read more

Deutsche Bank Flagged $582 Million of Suspicious Epstein-Linked Payments in US Filings and Once Mistakenly Sent Out Trump’s Tax Statements, Leaked Documents Show

by Team Lumida
9 hours ago

Leaked documents show Deutsche Bank filed US suspicious activity reports on $582 million of Epstein-linked transfers and once mistakenly sent Trump’s tax statements.

Read more

S&P 500 Sinks 1.92% and Nasdaq 2.49% for a Third Straight Loss as Nvidia Drops 4.1%, With Futures Mixed Hours Before Its Earnings

by Team Lumida
9 hours ago

US stocks fell for a third day as Nvidia slid 4.1%, with the VIX jumping and futures mixed ahead of Nvidia’s results and retail sales data.

Read more

BlackRock Triples Its Equity Overweight to 3% and Broadens AI Bets in Its $300 Billion Model Portfolios, Pulling About $4.4 Billion From Its Treasury ETF

by Team Lumida
1 day ago
Is BlackRock the New Leader in Alternative Investments?

BlackRock lifted its equity overweight to 3% from 1% and broadened AI exposure in its $300 billion model portfolios, driving billions in ETF flows.

Read more

Nasdaq-100 Futures Drop 0.77% and SK Hynix Sinks 5.6% as Markets Brace for Nvidia’s First Post-Huang Earnings and Anthropic’s IPO

by Team Lumida
1 day ago
AI Bulls Trample Bond Market Warnings — S&P 500 Breaks 7,800 as Tech Rally Defies Elevated Yields, Fed Uncertainty, Global Tightening

US stock futures slipped and Asian chipmakers slid as investors braced for Nvidia's earnings and Anthropic's roughly $1.4 trillion IPO.

Read more

Nvidia’s 2031 Bond Yield Rises to 5.717% After Huang’s Exit, With $36 Billion of Neocloud Backstops Now Under Scrutiny

by Team Lumida
4 days ago

Nvidia’s 4.5% bond due 2031 yielded 5.717% on Friday, and analysts are questioning the company’s role in backing AI infrastructure after Jensen Huang’s exit.

Read more

S&P 500 Falls 0.4% and Nasdaq 0.91% on Friday as Nvidia Slides, but the Major Averages Notch Their Best Week Since August

by Team Lumida
4 days ago

The S&P 500 fell 0.4% and the Nasdaq 0.91% on Friday as Nvidia slid, but the major averages still scored their best week since August.

Read more

AI Borrowers Now Account for Almost Half of Long-Dated US Investment-Grade Issuance, With Hyperscaler Bond Sales Seen Near $250 Billion

by Team Lumida
5 days ago

AI-related borrowers now account for almost half of long-dated US investment-grade issuance, PIMCO said, urging credit diversifiers.

Read more

Nasdaq-100 Futures Slide 0.9% as Nvidia Falls More Than 8% After Hours, Leaving the Stock Down About 30% From Its Oct. 6 High

by Team Lumida
5 days ago

Nasdaq-100 futures fell 0.9% after Nvidia dropped more than 8% after hours on reports its board is preparing to oust CEO Jensen Huang.

Read more

CoreWeave Earnings Revive AI Outlook—168% Revenue Growth, FY Guidance Raised to $13-13.3B; Anthropic IPO Valuation Rebounds to $1.5T+; Nasdaq 100 Futures +1.5%; Bitcoin Steady $74K

by Team Lumida
6 days ago

CoreWeave Q3 revenue +168% YoY, net loss widened to $709M ($1.27/share) on higher interest costs. Raised FY2026 revenue guidance $13-13.3B. CRWV +10% premarket; AI infrastructure rally: IREN +6%,...

Read more
Next Post
white and blue glass walled high rise building

NYC Real-Estate Firm Nears Deal to Buy Troubled Office Landlord Paramount

red and whites logo

TikTok Buyers to Include Oracle, Silver Lake and Andreessen

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

Inflation Eases: Will Powell Signal Rate Cuts Soon?

US Futures Soar: What Powell’s Congress Testimony Could Mean for Investors

July 9, 2024
Micron Stock Plummets Despite Surging AI Demand – What’s Next?

Micron Stock Plummets Despite Surging AI Demand – What’s Next?

June 27, 2024
House Rebuke of Canada Tariffs Exposes Political Risk Around Trump’s Trade Agenda

Trump Signals He’ll End the Iran War With Hormuz Still Closed — and Leave the Cleanup to Allies

March 31, 2026

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Legacy
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Opinions
    • Investing Philosophy
    • Op-Ed
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Investing Philosophy
  • Latest
  • Legacy
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Op-Ed
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bank of America China Commercial Real Estate CPI data centers Donald Trump EARNINGS ELON MUSK Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Novo Nordisk Nuclear Energy Nvidia oil OpenAI private equity S&P 500 SEC Semiconductor stock market stock surge Tech Stocks tesla Trump Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018